Organization
Aileron Therapeutics
2 clinical trials
1 abstract
Clinical trial
A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced MyelosuppressionStatus: Terminated, Estimated PCD: 2022-07-30
Clinical trial
A Phase 1b Clinical Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, as a Chemoprotection Agent in Patients With TP53-Mutated, HER2 Negative Breast Cancer Receiving Neoadjuvant or Adjuvant Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)Status: Terminated, Estimated PCD: 2023-02-22
Abstract
Targeted inhibition of IRAK-4 with emavusertib on immune remodeling in metastatic brain melanoma.Org: University of Florida Department of Health Outcomes and Biomedical Informatics, Gainesville, FL, University of Florida College of Public Health and Health Professions, Aileron Therapeutics, Watertown, MA,